Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712362 | 0.91 | NR1H4 (0.53) | NR1H4CYP2C9CYP3A4CYP2D6KCNH2 | |
| SCHEMBL1712565 | 0.89 | NR1H4 (0.48) | NR1H4CYP2C9CYP3A4CYP2D6KCNH2 | |
| SCHEMBL1712213 | 0.85 | NR1H4 (0.45) | NR1H4CYP2C9CYP3A4CYP2D6KCNH2 | |
| SCHEMBL1712084 | 0.85 | NR1H4 (0.53) | NR1H4CYP2C9CYP3A4CYP2D6KCNH2 | |
| SCHEMBL2383081 | 0.85 | NR1H4 (0.54) | NR1H4CYP2C9CYP3A4CYP2D6KCNH2 | |
| SCHEMBL2381664 | 0.85 | NR1H4 (0.53) | NR1H4CYP2C9CYP3A4CYP2D6KCNH2 | |
| SCHEMBL1712658 | 0.84 | NR1H4 (0.52) | NR1H4CYP2C9CYP3A4CYP2D6KCNH2 | |
| SCHEMBL1712381 | 0.83 | NR1H4 (0.42) | NR1H4CYP2C9CYP3A4CYP2D6KCNH2 | |
| SCHEMBL1712510 | 0.82 | NR1H4 (0.44) | NR1H4CYP2C9CYP3A4CYP2D6KCNH2 | |
| SCHEMBL1712624 | 0.81 | NR1H4 (0.42) | NR1H4CYP2C9CYP3A4CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344459-B1 | 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES | HOFFMANN LA ROCHE (CH) | 2013-12-25 | — | — | EP | claimed |
| US-8008505-B2 | Indazole or 4,5,6,7-tetrahydro-indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-30 | — | — | US | claimed |
| EP-2344459-A1 | 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES | F. Hoffmann-La Roche AG (CH) | 2011-07-20 | — | — | EP | claimed |
| WO-2010034649-A1 | 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-01 | — | — | WO | claimed |
| US-20100076027-A1 | INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-03-25 | — | — | US | claimed |
| EP-2344459-B1 | 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES | HOFFMANN LA ROCHE (CH) | 2013-12-25 | — | — | EP | disclosed |
| US-8008505-B2 | Indazole or 4,5,6,7-tetrahydro-indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008505-B2 | Indazole or 4,5,6,7-tetrahydro-indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-30 | — | — | US | disclosed |
| EP-2344459-A1 | 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES | F. Hoffmann-La Roche AG (CH) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010034649-A1 | 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010034649-A1 | 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-01 | — | — | WO | disclosed |
| US-20100076027-A1 | INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-03-25 | — | — | US | disclosed |
| US-20100076027-A1 | INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076027-A1 | INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | NR1H4, ABCB11, FXR1 | NR1H4 1/4885CYP2C9 92/4885CYP3A4 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.